CAR-T cell therapy market for Non-Hodgkin lymphoma

As per DelveInsight, the CART Cell Therapy Market size for Non-Hodgkin Lymphoma in the 6MM (the US, EU5 (the UK, Germany, France, Italy and Spain)) is expected to be USD 2796.2 Million by 2030.

Among the EU-5 countries, Germany, Italy and France are observed to be among top holders of the largest CAR T-Cell Therapy market share for Non-Hodgkin lymphoma followed by UK and Spain.
Several companies, including Celgene, and Gilead Sciences, are working to fuel the CAR-T cell therapy market for Non-Hodgkin lymphoma. The expected launch of Lisocabtagene maraleucel (also known as JCAR017) of Celgene’s, (a Bristol Myers Squibb company) and KTE-X19 by Gilead Sciences will significantly drive the NHL market in the near future.

For more details visit: https://www.delveinsight.com/blog/car-t-cell-therapy-market-for-non-hodgkin-lymphoma/

#CART #CellTherapy #Lymphoma #CARTMarket #CARTCellTherapy #healthcare #pharmaceuticals #lifesciences #marketresearch #biotechnology